The gut microbiome and metabolic syndrome

Dabke, Kruttika; Hendrick, Gustaf; Devkota, Suzanne

doi:10.1172/jci129194

Cited by 443 publications

(371 citation statements)

References 90 publications

(104 reference statements)

Supporting

Mentioning

351

Contrasting

Unclassified

Order By: Relevance

“…Currently, to the best of our knowledge, there has not been a meta-analysis only in patients with a specific diagnosis of MetS published, excluding people with type 2 diabetes. MetS, as a cluster of anthropometric, clinicalm and metabolic abnormalities, has had different definitions developed under the auspices of diverse scientific societies and some of the cut-offs of its criteria vary [28]. In the present review, the included studies used the National Cholesterol Education Program Adult Treatment Panel III criteria [16][17][18]22,23], obesity accompanied by arterial hypertonia [21], and the IDF criteria [19,20,24].…”

Section: Discussionmentioning

confidence: 99%

Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials

et al. 2020

View full text Add to dashboard Cite

The aim of this systematic review is to evaluate whether the use of probiotics has any effect on the components of metabolic syndrome (MetS) before patients develop type 2 diabetes. A qualitative systematic review, following the Cochrane methodology, and a comprehensive literature search of randomized controlled trials (RCTs) were conducted in PubMed and Scopus from inception until 4 July 2019. According to our inclusion criteria, nine clinical studies were finally analyzed, corresponding to six RCTs. Probiotics intake in patients with MetS resulted in improvements in body mass index, blood pressure, glucose metabolism, and lipid profile in some studies. Regarding inflammatory biomarkers, probiotics also positively affected the soluble vascular cell adhesion molecule 1 (sVCAM-1), interleukine-6 (IL-6), tumor necrosis factor α (TNF-α), vascular endothelial growth factor (VEGF), and thrombomodulin. Despite the diversity of the published studies, the intake of probiotics for patients with MetS may offer a discrete improvement in some of the clinical characteristics of the MetS and a decrease in inflammatory biomarkers. Nevertheless, these beneficial effects seem to be marginal compared to drug therapy and a healthy lifestyle and clinically non-relevant.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although there is no single definition for MetS [22], this pathological condition groups a constellation of metabolic factors that increase the risk of cardiovascular diseases (CVDs) (raised triglycerides, blood pressure, and glucose, reduced high-density lipoprotein cholesterol (HDLc), and central abdominal obesity) [23]. The gut microbiota composition and its potential role in MetS have been previously described [9,[24][25][26][27][28], but the possible impact of drug treatments and(or) the specific cardiovascular risk factors in the composition and functionality of the gut microbiota from MetS patients have not been addressed. Similarly, the microbiota in animal MetS models is well characterized [26,29].…”

Section: Introductionmentioning

confidence: 99%

“…The gut microbiota composition and its potential role in MetS have been previously described [9,[24][25][26][27][28], but the possible impact of drug treatments and(or) the specific cardiovascular risk factors in the composition and functionality of the gut microbiota from MetS patients have not been addressed. Similarly, the microbiota in animal MetS models is well characterized [26,29]. However, the induction of MetS in these models is different, and the medication is not present [30].…”

Section: Introductionmentioning

confidence: 99%

There is No Distinctive Gut Microbiota Signature in the Metabolic Syndrome: Contribution of Cardiovascular Disease Risk Factors and Associated Medication

et al. 2020

View full text Add to dashboard Cite

The gut microbiota (GM) has attracted attention as a new target to combat several diseases, including metabolic syndrome (MetS), a pathological condition with many factors (diabetes, obesity, dyslipidemia, hypertension, etc.) that increase cardiovascular disease (CVD) risk. However, the existence of a characteristic taxonomic signature associated with obesity-related metabolic dysfunctions is under debate. To investigate the contribution of the CVD risk factors and(or) their associated drug treatments in the composition and functionality of GM in MetS patients, we compared the GM of obese individuals (n = 69) vs. MetS patients (n = 50), as well as within patients, depending on their treatments. We also explored associations between medication, GM, clinical variables, endotoxemia, and short-chain fatty acids. Poly-drug treatments, conventional in MetS patients, prevented the accurate association between medication and GM profiles. Our results highlight the heterogeneity of taxonomic signatures in MetS patients, which mainly depend on the CVD risk factors. Hypertension and(or) its associated medication was the primary trait involved in the shaping of GM, with an overabundance of lipopolysaccharide-producing microbial groups from the Proteobacteria phylum. In the context of precision medicine, our results highlight that targeting GM to prevent and(or) treat MetS should consider MetS patients more individually, according to their CVD risk factors and associated medication.

show abstract

“…Meanwhile, the intestinal ora is involved in metabolic diseases such as obesity and dyslipidemia of the organism. The interplay of the gut microbiota with host can be mediated by diet, and its effects starts but is far beyond the intestine (Dabke et al 2019). At present, antibiotics are widely used in animal husbandry and weight gain by gut microbiota manipulation to improve the growth performance of animals (Angelakis 2017).…”

Section: Introductionmentioning

confidence: 99%

Dietary Purslane (Portulaca Oleracea L.) Promotes the Growth Performance of Broilers by Modulation of Gut Microbiota

Huang

Liu

Ye³

et al. 2020

Preprint

View full text Add to dashboard Cite

Purslane is a widespread wild vegetable with both medicinal and edible properties. It is highly appreciated for its high nutritional value and is also considered as a high-quality feed resource for livestock and poultry. In this study, Sanhuang broilers were used to investigate the effect of feeding purslane diets on the growth performance in broilers and their gut microbiota. A total of 48 birds with good growth and uniform weight were selected and randomly allocated to four treatment groups A (control), B, C and D. Dietary treatments were fed with basal diet without purslane and diets containing 1%, 2% and 3% purslane. The 16S rDNA was amplified by PCR and sequenced using the Illumina HiSeq platform to analyze the composition and diversity of gut microbiota in the four sets of samples. The results showed that dietary inclusion of 2% and 3% purslane could significantly improve the growth performance and reduce the feed conversion ratio. Microbial diversity analysis indicated that the composition of gut microbiota of Sanhuang broilers mainly included Gallibacterium, Bacteroides and Escherichia-Shigella, etc. As the content of purslane was increased, the abundance of Lactobacillus increased significantly, and Escherichia-Shigella decreased. LEfSe analysis revealed that Bacteroides_caecigallinarum, Lachnospiraceae, Lactobacillales and Firmicutes had significant differences compared with the control group. PICRUSt analysis revealed bacteria mainly enriched in carbohydrate metabolism pathway due to the additon of purslane in the diet. These results suggest that the addition of purslane to feed could increase the abundance of Lactobacillus in intestine, modulate the environment of gut microbiota and promote the metabolism of carbohydrates to improve its growth performance. This study indicates that the effect of purslane on the growth-promoting performance of broilers might depend on its modulation on gut microbiota, so as to provide a certain scientific basis for the application of purslane in the feed industry.

show abstract

The gut microbiome and metabolic syndrome

Abstract: Conflict of interest: SD is a consultant for the Janssen Human Microbiome Institute and a named inventor on a patent application related to intestinal microbiota.

Cited by 443 publications

References 90 publications

Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials

Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials

There is No Distinctive Gut Microbiota Signature in the Metabolic Syndrome: Contribution of Cardiovascular Disease Risk Factors and Associated Medication

Dietary Purslane (Portulaca Oleracea L.) Promotes the Growth Performance of Broilers by Modulation of Gut Microbiota

Contact Info

Product

Resources

About